Patents Examined by Marianne P. Allen
  • Treatment of psychiatric conditions
    Patent number: 11191831
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: December 7, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Relaxin fusion polypeptides and uses thereof
    Patent number: 11192931
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: December 7, 2021
    Assignees: Medlmmune, LLC, Medlmmune Limited
    Inventors: Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
  • Serum albumin binding proteins containing immunoglobulin single variable domains
    Patent number: 11192938
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 7, 2021
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
    Patent number: 11192937
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 7, 2021
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Methods of treating cancer using bifunctional molecules that target growth factors
    Patent number: 11186632
    Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 30, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Li Mao, Hening Ren
  • Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
    Patent number: 11180539
    Abstract: An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease. A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: November 23, 2021
    Assignee: KARYDO THERAPEUTIX, INC.
    Inventor: Narutoku Sato
  • Method for producing an active hepatocyte growth factor (HGF)
    Patent number: 11168123
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
    Patent number: 11154622
    Abstract: The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: October 26, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Dimki S. Patel, Amit N. Patel
  • Method for preserving and stabilizing proteins for formulations of sanitary, pharmaceutical and cosmetic products
    Patent number: 11147882
    Abstract: A method for preserving and stabilizing proteins includes the steps of forming an anhydrous medium having oily phase components having hydrophilic residues, and dispersing the proteins into the anhydrous medium under ambient pressure and temperature conditions so that the proteins are incorporated into the anhydrous medium so as to maintain an active formation of the proteins.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 19, 2021
    Inventor: Teodoro Mayayo Falo
  • Fusion proteins with extended serum half life
    Patent number: 11141463
    Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 12, 2021
    Assignees: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
    Inventors: Ari-Angel Porgador, David Ben-Menahem, Roee Atlas
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11130804
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • Humanized anti-ACTH antibodies and use thereof
    Patent number: 11117960
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 14, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
  • Compositions for increasing polypeptide stability and activity, and related methods
    Patent number: 11118169
    Abstract: This disclosure provides peptides, polypeptides, fusion polypeptides, compositions, and methods for enhancing or increasing the stability of a polypeptide (e.g., Taq polymerase). Such peptides, polypeptides, fusion polypeptides, or compositions include polypeptides linked to a peptide tag that enhances the stability of the polypeptide. The peptides, polypeptides, fusion polypeptides, compositions may also enhance the activity, specificity, and/or fidelity of other polypeptides in a reaction mixture. The disclosure also provides methods of using such peptides, polypeptides, fusion polypeptides, compositions.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 14, 2021
    Assignee: Solis BioDyne OÜ
    Inventors: Olev Kahre, Kadri Artma, Tiina Kahre
  • Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum
    Patent number: 11117939
    Abstract: The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 14, 2021
    Assignee: University of Sasketchewan
    Inventors: Changiz Taghibiglou, Yu Tian Wang
  • Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia
    Patent number: 11111282
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 7, 2021
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • Modified fibroblast growth factors for the treatment of ocular disorders
    Patent number: 11103553
    Abstract: Described herein are modified fibroblast growth factors (FGFs), pharmaceutical compositions, ophthalmic formulations, and medicaments that include such modified FGFs, and methods of using such modified FGFs to treat ocular diseases, disorders, or conditions.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 31, 2021
    Assignee: TREFOIL THERAPEUTICS, INC.
    Inventors: David Eveleth, Kenneth A. Thomas, Jr.
  • Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
    Patent number: 11059906
    Abstract: The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Paolo G. V. Martini, Madhusudan Natarajan, Patrick Anthony John Haslett, Albert Barnes Seymour
  • Pharmaceutical preparation stably comprising CD147 monoclonal antibody
    Patent number: 11053317
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: July 6, 2021
    Assignee: JIANGSU PACIFIC MEINUOKE BIO-PHARMACEUTICAL CO., LTD.
    Inventors: Hao Tang, Qiang Feng, Xiaochun Chen
  • Heavy chain only antibodies to PDGF
    Patent number: 11028163
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 8, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Pharmaceutical preparation stably comprising CD147 monoclonal antibody
    Patent number: 11027016
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 8, 2021
    Inventor: Xiaochun Chen